JP2019531743A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531743A5 JP2019531743A5 JP2019520742A JP2019520742A JP2019531743A5 JP 2019531743 A5 JP2019531743 A5 JP 2019531743A5 JP 2019520742 A JP2019520742 A JP 2019520742A JP 2019520742 A JP2019520742 A JP 2019520742A JP 2019531743 A5 JP2019531743 A5 JP 2019531743A5
- Authority
- JP
- Japan
- Prior art keywords
- endogenous
- cell
- immune cells
- immune
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662410187P | 2016-10-19 | 2016-10-19 | |
| US62/410,187 | 2016-10-19 | ||
| DKPA201670840 | 2016-10-27 | ||
| DKPA201670840 | 2016-10-27 | ||
| PCT/EP2017/076798 WO2018073391A1 (en) | 2016-10-19 | 2017-10-19 | Targeted gene insertion for improved immune cells therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019531743A JP2019531743A (ja) | 2019-11-07 |
| JP2019531743A5 true JP2019531743A5 (cg-RX-API-DMAC10.html) | 2020-11-12 |
| JP7274416B2 JP7274416B2 (ja) | 2023-05-16 |
Family
ID=60268351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520742A Active JP7274416B2 (ja) | 2016-10-19 | 2017-10-19 | 改善された免疫細胞療法のための標的指向遺伝子挿入 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11873511B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3529351A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7274416B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR102709329B1 (cg-RX-API-DMAC10.html) |
| CN (1) | CN110023490B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2017347637B2 (cg-RX-API-DMAC10.html) |
| BR (1) | BR112019007715A2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3040048A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL265953B2 (cg-RX-API-DMAC10.html) |
| MX (1) | MX2019004215A (cg-RX-API-DMAC10.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018001232A2 (pt) | 2015-07-21 | 2018-09-25 | The Children's Medical Center Corporation | pd-l1 que expressa células-tronco hematopoéticas e usos |
| WO2019060708A1 (en) | 2017-09-22 | 2019-03-28 | The Children's Medical Center Corporation | TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS |
| CN110841058B (zh) * | 2019-11-21 | 2022-09-02 | 北京启辰生生物科技有限公司 | 用于协同改善免疫应答的组合物及应用 |
| CN110790842B (zh) * | 2019-11-25 | 2021-03-30 | 贵州康钦承平生物科技有限公司 | 一种FasL-CAR融合蛋白和表达融合蛋白的T细胞及其制备方法和应用 |
| EP4171616A1 (en) * | 2020-06-26 | 2023-05-03 | Juno Therapeutics GmbH | Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| IL303269A (en) | 2020-12-03 | 2023-07-01 | Century Therapeutics Inc | Genetically engineered cells and uses thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
| EP4271798A1 (en) | 2020-12-30 | 2023-11-08 | CRISPR Therapeutics AG | Compositions and methods for differentiating stem cells into nk cells |
| KR102491095B1 (ko) * | 2021-01-22 | 2023-01-20 | 한국생명공학연구원 | Cas 단백질 및 HIF의 TAD 도메인을 포함하는 단백질 융합체 및 이의 용도 |
| KR102500873B1 (ko) * | 2021-02-03 | 2023-02-17 | 한국과학기술연구원 | 자연살해세포 특이적 CRISPR/Cas 시스템을 위한 융합 단백질 및 이의 용도 |
| WO2022242700A1 (en) * | 2021-05-20 | 2022-11-24 | Wuxi Biologics (Shanghai) Co., Ltd. | Genetically modified nk cells and uses thereof |
| EP4341300A1 (en) * | 2021-05-21 | 2024-03-27 | Cellectis S.A. | Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumors |
| WO2022269393A1 (en) * | 2021-06-23 | 2022-12-29 | Crispr Therapeutics Ag | Engineered cells with improved protection from natural killer cell killing |
| CN113604437A (zh) * | 2021-08-13 | 2021-11-05 | 青岛华赛伯曼医学细胞生物有限公司 | 过表达ccr2的免疫细胞及其应用 |
| US20250319144A1 (en) * | 2021-11-19 | 2025-10-16 | Nankai University | Recombinant Armed Oncolytic Virus Composition and Use Thereof in TIL Adoptive Therapy |
| JP2025524921A (ja) * | 2022-07-29 | 2025-08-01 | レジェンド バイオテック アイルランド リミテッド | 細胞療法の持続性を促進するための方法 |
| CN115820697B (zh) * | 2022-09-23 | 2024-07-30 | 中国海洋大学 | 一种免疫细胞及其制备方法和应用 |
| CN115286697B (zh) * | 2022-09-29 | 2022-12-13 | 烟台蓝纳成生物技术有限公司 | 一种双重靶向化合物及其制备方法和应用 |
| CN115851909B (zh) * | 2022-11-21 | 2023-09-08 | 郑州大学第一附属医院 | 检测fosb基因的试剂在制备诊断腹主动脉瘤产品的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201806573TA (en) * | 2012-05-25 | 2018-09-27 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| CA2912375C (en) * | 2013-05-13 | 2023-03-14 | Cellectis | Methods for engineering highly active t cell for immunotherapy |
| JP6608807B2 (ja) * | 2013-05-29 | 2019-11-20 | セレクティス | Ｒｎａガイドｃａｓヌクレアーゼ系を用いることによって免疫療法のためにｔ細胞を操作するための方法 |
| JP6976058B2 (ja) | 2013-11-22 | 2021-12-01 | セレクティスCellectis | 免疫療法のための化学療法薬耐性ｔ細胞を工学的に作製する方法 |
| RU2752933C2 (ru) * | 2014-03-11 | 2021-08-11 | Селлектис | Способ создания т-клеток, пригодных для аллогенной трансплантации |
| US20190024065A1 (en) | 2015-02-06 | 2019-01-24 | Cellectis | Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles |
| BR112017020750A2 (en) * | 2015-03-27 | 2018-06-26 | President And Fellows Of Harvard College | modified t-cells and methods of producing and using them |
| EP4339287A3 (en) * | 2015-07-31 | 2024-05-22 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
| KR102614675B1 (ko) * | 2016-04-15 | 2023-12-19 | 메모리얼 슬로안 케터링 캔서 센터 | 유전자이식 t 세포 및 키메라 항원 수용체 t 세포 조성물 및 관련 방법 |
-
2017
- 2017-10-19 IL IL265953A patent/IL265953B2/en unknown
- 2017-10-19 JP JP2019520742A patent/JP7274416B2/ja active Active
- 2017-10-19 EP EP17794689.4A patent/EP3529351A1/en active Pending
- 2017-10-19 MX MX2019004215A patent/MX2019004215A/es unknown
- 2017-10-19 KR KR1020197013626A patent/KR102709329B1/ko active Active
- 2017-10-19 BR BR112019007715-4A patent/BR112019007715A2/pt unknown
- 2017-10-19 CN CN201780072672.5A patent/CN110023490B/zh active Active
- 2017-10-19 US US16/340,222 patent/US11873511B2/en active Active
- 2017-10-19 CA CA3040048A patent/CA3040048A1/en active Pending
- 2017-10-19 AU AU2017347637A patent/AU2017347637B2/en active Active
-
2023
- 2023-12-14 US US18/540,309 patent/US12391933B2/en active Active
-
2025
- 2025-07-21 US US19/274,947 patent/US20260103694A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12391933B2 (en) | Targeted gene insertion for improved immune cells therapy | |
| US12209125B2 (en) | Targeted gene integration of NK inhibitors genes for improved immune cells therapy | |
| US11834502B2 (en) | Reducing immune inhibition induced by SIGLEC-15 | |
| CA3151690A1 (en) | Genetically-edited immune cells and methods of therapy | |
| WO2018073391A1 (en) | Targeted gene insertion for improved immune cells therapy | |
| US11788072B2 (en) | Activation of APC in immunotherapy | |
| US20220105134A1 (en) | Modified cell and use thereof in gene and cell therapy | |
| WO2019025800A1 (en) | CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE | |
| WO2019106163A1 (en) | Reprogramming of genetically engineered primary immune cells | |
| US20190290694A1 (en) | Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy | |
| US20240075061A1 (en) | Cell therapy activating lymphocyte in tme | |
| EP4540372A1 (en) | Method for expanding immune cells | |
| RU2824204C2 (ru) | Инсерция таргетного гена для улучшенной клеточной иммунотерапии | |
| WO2024256627A1 (en) | Novel innate lymphoid cells (ilcs) | |
| CN120091826A (zh) | 多发性硬化症的细胞疗法 | |
| Dahiya et al. | Genome Engineering Tools in Immunotherapy | |
| CN121511315A (zh) | 选择nk细胞供体来源的方法 | |
| June | Cell therapy for cancer–our synthetic future | |
| Hu et al. | Donor Natural Killer Cells and Their Therapeutic Potential in Allogeneic Hematopoietic Stem Cell |